Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer-Reference-Cited by-同舟云学术

Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer

Published:2023-12 Issue: Volume: Page:
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Small Eric J.,Chi Kim N.,Chowdhury Simon,Bevans Katherine B.,Bhaumik Amitabha,Saad Fred,Chung Byung Ha,Karsh Lawrence I.,Oudard Stéphane,De Porre Peter,Brookman-May Sabine D.,McCarthy Sharon A.,Mundle Suneel D.,Uemura Hirotsugu,Smith Matthew R.,Agarwal Neeraj

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference27 articles.

1. National Comprehensive Cancer Network. Prostate cancer. Version 4.2022-May 10, 2022. 2022. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

2. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3;Scher;J Clin Oncol,2016

3. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer;Armstrong;J Clin Oncol,2019

4. Apalutamide for metastatic castration-sensitive prostate cancer in TITAN: prognostic importance of prostate-specific antigen responses;Chowdhury;J Urol,2020

5. Deep prostate-specific antigen response following addition of apalutamide to ongoing androgen deprivation therapy and long-term clinical benefit in SPARTAN;Saad;Eur Urol,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer;European Urology;2024-08

2. PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC);Clinical and Translational Oncology;2024-07-29

3. Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy;BJU International;2024-06-28

4. Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients;The Prostate;2024-05-29